LEVERKUSEN, Germany (AP) — Victor Boniface's added-time goal lifted Bayer Leverkusen to a 4-3 comeback win over Wolfsburg in ...

Victor Boniface delivered a 93rd-minute winner as Bayer Leverkusen pulled off a stunning Bundesliga comeback for a 4-3 victory over Wolfsburg on Sunday. Nordi Mukiele turned into his own net in the ...

LEVERKUSEN, Germany (AP) — Victor Boniface's added-time goal lifted Bayer Leverkusen to a 4-3 comeback win over Wolfsburg in ...

This summer was characterised as much by the deals that didn’t happen, with champions Bayer Leverkusen managing to retain all the core players who led them to a first-ever top-flight title ...

In an exclusive interview with Sky Sports, Bayer Leverkusen’s academy director explains how they want to become the talk of Europe again; after the Bundesliga title comes plans for their academy ...

Bayer Leverkusen and RB Leipzig both get their Bundesliga campaigns off to winning starts but one or both will falter when they meet this weekend. Champions Leverkusen needed a last-gasp Florian ...

Bayer BAYRY announced encouraging detailed results from the late-stage FINEARTS-HF study on finerenone. Finerenone is marketed as Kerendia or Firialta in some countries. The drug is approved for ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €34.00. The company’s shares closed last Friday at €27.90.

With the heart failure (HF) patient population rapidly expanding, the timing is right for Bayer’s Kerendia (finerenone). The nonsteroidal mineralocorticoid receptor antagonist (MRA) was approved ...

Discover for yourself - whether privately or on business - the first-class service at Bayer 04 Leverkusen and become part of the club under the Bayer Cross. Versatile, multifunctional: in the BayArena ...

The record German champions, who were upstaged last season by Bayer Leverkusen, appointed former Burnley manager Kompany to succeed Thomas Tuchel after their disappointing third-place finish last ...

Bayer suspended the phase 3 trial for its factor XIa inhibitor asundexian late last year after the drug showed “inferior efficacy” at preventing strokes in patients with atrial fibrillation ...